Lupin Digital Health's Lyfe Platform gets Class C Medical Device license from CDSCO

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-04-25 10:53 GMT   |   Update On 2024-04-25 10:53 GMT
Advertisement

Mumbai: Lupin Digital Health, India's evidence-based cardiology Digital Therapeutics (DTx) platform, has announced that its Lyfe platform has received approval as a Class C Medical Device from the Central Drugs Standard Control Organization (CDSCO). 

"Having undergone a rigorous application, review, and on-site audit process, this Class C Medical Device license reaffirms the platform's effectiveness and emphasizes its commitment to quality, safety, and rigour.

Advertisement

Lyfe is now India's first clinically proven remote cardiac rehabilitation program, designed to enhance heart health and quality of life. By providing tailored, accessible solutions in the comfort of patients' homes, Lyfe empowers individuals to confidently manage their heart health," the Company stated.

Commenting about this recognition, Rajeev Sibal, President - India Region Formulations, Lupin, stated, "This approval reaffirms our dedication to excellence in cardiac care. We are proud to be at the forefront of digital therapeutics in India, signifying our commitment to supporting cardiologists with patient-centric solutions and improving cardiovascular outcomes."

Elaborating on the significance of receiving this license, Sidharth Srinivasan, CEO, Lupin Digital Health added, "Securing the Class C Medical Device license for Lyfe is a significant achievement. It validates Lyfe as a best-in-class platform to support millions of cardiac patients in India. This recognition will also encourage more cardiologists, hospitals and insurers to adopt remote cardiac rehabilitation for improved patient health outcomes.”

Read also: Lupin Digital Health CEO Sidharth Srinivasan Explores the Transformative Impact of Digital Therapeutics

Lupin Digital Health, a subsidiary of Lupin Limited, a leading global pharmaceutical company, developing advanced digital health solutions. Their primary offering, Lyfe, is a remote cardiac rehabilitation program powered by artificial intelligence (AI) and machine learning (ML). Through Digital Therapeutics, Lyfe offers health guidance, empowering individuals to manage their well-being proactively. With its integrated health monitoring devices, easy technological access, and the expertise of top cardiologists, Lyfe delivers a comprehensive cardiac care solution.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News